Navigation Links
Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting

Data From the Companies' Novel Heat Shock Protein 90 Inhibitor Reveal Further Evidence of Safety, Tolerability, and Biological Activity

CAMBRIDGE, Mass. and GAITHERSBURG, Md., June 5, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune, Inc. (Nasdaq:MEDI) today announced updated interim results from a Phase I clinical trial of the companies' heat shock protein 90 (Hsp90) inhibitor, IPI-504, in patients with relapsed, refractory gastrointestinal stromal tumors (GIST) and other advanced soft tissue sarcomas. The data, presented at the 2007 Annual Meeting of the American Society for Clinical Oncology (ASCO), indicate that IPI-504 continues to be well tolerated and to show evidence of biological activity.

To date, 28 patients have received IPI-504 on two schedules of administration at dose levels ranging from 90 to 400 mg/m2. Assessment of biological activity in response to IPI-504 administration utilized positron emission tomography (PET) imaging to measure the decrease in tumor uptake of 18-fluorodeoxyglucose, an imaging agent used to measure metabolic activity. Scans were taken at baseline and during the first cycle of treatment after at least two doses. PET results for "Schedule A" (21-day cycle with patients treated on days 1, 4, 8, and 11, followed by 10 days off treatment) were assessed using the European Organization for Research and Treatment of Cancer's (EORTC) PET response criteria which entails a quantitative measurement using SUVmax (maximum standardized uptake value). PET results for "Schedule B" (uninterrupted twice-weekly dosing without a drug holiday) were assessed qualitatively. (See below for additional information about PET imaging and SUVmax.)

EORTC criteria for PET responses define Stable Disease as a change in SUVmax between 25 percent above and 25 percent below baseline, and a Partial Response as a decrease in SUVmax of 25 percent or more
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
2. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
5. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
6. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
7. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
8. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
9. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
10. The Past, Present and Future of HLA Typing
11. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:8/31/2015)... Regen BioPharma, Inc. (OTCBB: RGBP) and ... means of delivering its patented (US Patent 8,263,571) ... utilizing a clinically approved formulation as delivery system.  ... gene silencing therapeutics in which the gene silencing ... body.  By utilizing a local delivery system, potential ...
(Date:8/31/2015)... and MOUNTAIN VIEW, Calif. , ... SNY ; EURONEXT: SAN) and the life sciences team ... improve care and outcomes for people with type 1 ... diabetes treatments and devices with Google,s expertise in analytics, ... will explore how to improve diabetes care by developing ...
(Date:8/31/2015)... 31, 2015  Qualcomm Incorporated (NASDAQ: QCOM ... Life, Inc., is collaborating with Davita Healthcare ... solutions powered by Qualcomm Life,s 2net™ Device Connectivity ... continuous care, informed interventions and better management of ... Life,s annual Connect 2015 ecosystem conference ...
Breaking Medicine Technology:Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5
... (NYSE: CFN ), a leading, global medical ... to sell its OnSite Services instrument management and ... were not disclosed. (Logo:   http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO ) ... with our strategy to optimize our portfolio of businesses as ...
... 11, 2011 Reportlinker.com announces that a new ... Advanced Drug Delivery Markets (Liposomes, ... http://www.reportlinker.com/p0358466/Advanced-Drug-Delivery-Markets-Liposomes-Polymers-and-Monoclonal-Antibodies.html Drug delivery is evolving ... formulations being discovered frequently. Advanced drug delivery deals ...
Cached Medicine Technology:CareFusion Announces Sale of OnSite Services Instrument Management and Repair Business 2CareFusion Announces Sale of OnSite Services Instrument Management and Repair Business 3Reportlinker Adds Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) 2Reportlinker Adds Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) 3
(Date:9/1/2015)... ... ... Dr. Trace Curry successfully placed one of the first ORBERA™ Intra-gastric Balloons in ... has approved two intra-gastric balloons, the ORBERA ™ Managed Weight Loss System and ... loss procedures available to Americans. , Dr. Curry, medical director at JourneyLite, ...
(Date:9/1/2015)... ... , ... Elizabeth Callahan, MD, founder and medical director of SkinSmart Dermatology® ... RADIESSE® filler treatment for volume loss in the hands. RADIESSE provides an immediate volumizing ... hands, delivering smooth, natural-looking results that can last up to one year in most ...
(Date:9/1/2015)... , ... September 01, 2015 , ... September is Baby ... manufacturers use safety labels and stickers to keep little ones' safety top of mind ... Safety Month has a particular focus. According to the JPMA's Baby Safety Zone website, ...
(Date:8/31/2015)... ... ... The PT Outcomes Registry is an organized system for collecting data to evaluate ... being developed by the American Physical Therapy Association (APTA). , Al Amato, PT, MBA, ... FOTO Outcomes measures as one of the primary global outcomes measures to be used ...
(Date:8/31/2015)... Oaks, CA (PRWEB) , ... August 31, 2015 ... ... recently been updated to include a wealth of information for specific translation services ... has great expertise and an incredible track record of successful work. , ITC ...
Breaking Medicine News(10 mins):Health News:Dr. Trace Curry Performs First ORBERA™ Intra-gastric Balloon in Ohio at JourneyLite, a New Incisionless Option For The Treatment of Obesity 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 3Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3Health News:FOTO Selected as Official Registry Partner with Physical Therapy Outcomes Registry 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 3
... Blue Cross and Blue,Shield of Oklahoma is announcing ... medical-dental program. The program is,unique in the industry ... to create a customized plan aimed to improve ... help users optimize their overall,health by making better ...
... fingerprint associated with normal embryonic stem cells may be ... cells. The research, published by Cell Press in the ... embryonic stem cells and multiple types of human cancer ... in normal differentiated cells, a finding that may have ...
... density, reduction in fractures, study finds , , WEDNESDAY, April ... safe and effective for women with mild to moderate ... risk, according to a new study. , The use ... controversial because it wasn,t known if the drugs were ...
... 2008 The Reproductive,Science Center of New ... for Ambulatory Health Care (AAAHC/Accreditation,Association), according to ... as an accredited organization means Reproductive Science ... of rigorous and nationally recognized,standards for the ...
... Being in Top 5% Nationwide in ... ... Providence Saint Joseph,Medical Center has received the Gold Seal of Approval(TM) ... third,hospital in Los Angeles County to receive this designation., This ...
... a hospital,is crowded on admission day, children may ... have less complicated illnesses that require ongoing assessment ... does not,affect the length of stay for children ... cell crises or bacterial meningitis., "Our findings ...
Cached Medicine News:Health News:Blue Cross and Blue Shield of Oklahoma Launches an Integrated Medical-Dental Health Program 2Health News:Blue Cross and Blue Shield of Oklahoma Launches an Integrated Medical-Dental Health Program 3Health News:Module map links embryonic stem cells and cancer stem cells 2Health News:Raloxifene Safe for Women With Decreased Kidney Function 2Health News:Reproductive Science Center of New England Receives Ambulatory Health Care Accreditation 2Health News:Providence Saint Joseph Medical Named LA County's Third Primary Stroke Center 2Health News:Admission-Day Crowding May Increase Hospital Stay for Children With Less Complicated Illnesses 2
High speed, programmable refrigerated centrifuge. High efficiency separations, "Like clockwork" accuracy, aerosol containment, Accommodating, Re-Run control, Glove-Friendly membrane, centrifuge statu...
... 460 family of centrifuges ... that meets a wide ... feature high capacity, versatility ... technology and high safety ...
The Quantum performs centrifugal blood cell separations, urine separations, and sperm cell washing. 24 place angle head, variable speed, and automatic braking system, calibrated variable speed....
... centrifuge is designed especially for ... cover with safety interlock switch, ... emissions, "hold" position for continuous ... motor, maximum stability and compact, ...
Medicine Products: